UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 10, 2012

CRYO-CELL INTERNATIONAL, INC.
(Exact Name of Registrant as Specified in its Charter)

Delaware
  
0-23386
  
22-3023093
(State or Other Jurisdiction
of Incorporation)
  
(Commission File No.)
  
(I.R.S. Employer
Identification No.)

700 Brooker Creek Blvd., Suite 1800, Oldsmar, Florida
  
34677
(Address of Principal Executive Offices)
  
(Zip Code)

Registrant’s telephone number, including area code:  (813) 749-2100

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
      CFR 240.14d-2(b))

[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
      CFR 240.13e-4(c))


 
 
 

Item 5.07                      Submission of Matters to a Vote of Security Holders

On July 10, 2012, Cryo-Cell International, Inc. (the “Company”) held its Annual Meeting of Stockholders.  At the Annual Meeting, shareholders considered the election of six directors, the ratification of independent registered public accountants and approval of the Company’s 2012 Equity Incentive Plan. 

The final result of the stockholder vote was certified on July 13, 2012 and is as follows:

1.  
To consider for election six individuals to the Company’s Board of Directors

Under plurality voting, the six nominees who received the most “FOR” votes were elected as directors.  The Company’s stockholders elected the Board of Director’s six nominees: Anthony Atala, M.D.; Harold Berger; David Portnoy; Mark Portnoy; George Gaines; and Jonathan Wheeler, M.D. as directors, each for a one-year term, as follows:


 
Anthony Atala, M.D.
      
 
For
  
4,989,956
  
 
Withhold
  
12,607
  
 
Broker non-votes
  
—
  
         
 
Harold Berger
      
 
For
  
4,989,956
  
 
Withhold
  
12,607
  
 
Broker non-votes
  
—
  
         
 
George Gaines
      
 
For
  
4,989,956
  
 
Withhold
  
12,607
  
 
Broker non-votes
  
—
  
         
 
David I. Portnoy
      
 
For
  
4,989,956
  
 
Withhold
  
12,607
  
 
Broker non-votes
  
—
  
         
 
Mark L. Portnoy
      
 
For
  
4,989,656
  
 
Withhold
  
12,607
  
 
Broker non-votes
  
—
  

 
 
 
 
Jonathan H. Wheeler, M.D.
      
 
For
  
4,989,956
  
 
Withhold
  
12,607
  
 
Broker non-votes
  
—
  
 
The stockholders did not approve the election of the following nominees:

 
Ajay Badlani
      
 
For
  
3,017,045
  
 
Withhold
  
11,615
  
 
Broker non-votes
  
—
  
         
 
Ki Yong Choi
      
 
For
  
3,018,419
  
 
Withhold
  
10,241
  
 
Broker non-votes
  
—
  
         
 
Michael W. Cho
      
 
For
  
3,017,045
  
 
Withhold
  
11,615
  
 
Broker non-votes
  
—
  
         
 
Michael D. Coffee
      
 
For
  
3,022,195
  
 
Withhold
  
6,465
  
 
Broker non-votes
  
—
  
         
 
Warren Hoeffler
      
 
For
  
3,023,195
  
 
Withhold
  
5,465
  
 
Broker non-votes
  
—
  
         
 
Gary D. Weinhouse
      
 
For
  
3,022,069
  
 
Withhold
  
6,591
  
 
Broker non-votes
  
—
  

 
 
 

2.
The ratification of the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending November 30, 2012.

For
Against
Abstain
Broker Non-Vote
       
7,484,861
550,722
5,200
—

3.
The approval of the Company’s 2012 Equity Incentive Plan.

For
Against
Abstain
Broker Non-Vote
       
4,890,109
3,107,964
33,150
—

Item 9.01                      Financial Statements and Exhibits

Not Applicable.


 
 
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

   
Cryo-Cell International, Inc.
 
 
DATE: July 13, 2012
By:
/s/ David I. Portnoy                                                              
   
David I. Portnoy,
Chairman and Co-Chief Executive Officer